Project Twenty21, an ambitious large-scale cannabis study originally based in the U.K. is now expanding into Australia where it is recruiting participants. The project, which was originally launched in 2019 has so far enrolled 2000 participants in the U.K. Its goal in Australia is to enlist at least 1000 participants, all of which will have access to low-cost cannabis medicines.
Project Twenty21 was launched in 2019 with the aims of establishing a large body of evidence on the efficacy and tolerability of medical cannabis, and providing patients with access to the medicine at a reduced price. Originally launched in the UK, it’s now in Australia and looking for participants.
If staying up to date with all the latest cannabis research like what Project Twenty21 is doing is of interest to you, simply download our free cannabis news app today.
Project Twenty21 First Extended in the UK
The latter goal of Project Twenty21 was achieved through partnerships with licensed producers to subsidize the cost; the quid pro quo being that patients had to consent to their medical data being collected by the organization leading the initiative, Drug Science.
Although Project Twenty21 fell short of its ambitious target of reaching 20,000 patients by the end of last year, with only 2,000 patients registered, it has been extended until the end of 2022 in the UK. This extension is accompanied by changes in the pricing of medical cannabis.
Project Twenty21 Extension to Australia
Drug Science announced that the project would also operate in Australia in collaboration with the Australasian College of Cannabinoid Medicine (ACCM), the research arm of Releaf Group.
The Australian arm of the Project Twenty21 study, which will be conducted at Releaf Clinics, will focus on collecting data on the efficacy and safety of medical cannabis in the treatment of chronic pain, anxiety, post-traumatic stress disorder (PTSD) and multiple sclerosis. People participating in the study will be asked to complete online questionnaires every three months for 12 months.
Reduced-price Cannabis Available to 1000+ Study Participants
“By engaging at least 1,000 patients locally, Project Twenty21 intends to track the outcomes of their medical cannabis treatments to gain valuable information that will help improve patient care in Australia,” said Releaf Group scientific director and researcher Professor Kylie O’Brien.
Among other Project Twenty21 criteria, eligible participants must be in the process of seeing or have just seen a Releaf Clinics clinician. People already using cannabis for medical purposes cannot participate. Cannabis-based medicines prescribed to study participants will be available at a reduced price for the duration of their participation.
The results of the Project Twenty21 study will be made public on the ACCM website and submitted to peer-reviewed journals for publication.
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in NewsWeed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.